Zobrazeno 1 - 10
of 291
pro vyhledávání: '"Carol Aghajanian"'
Autor:
Kelsey Breen, Zsofia K. Stadler, Rachel N. Grisham, Kara Long Roche, Deborah J. Goldfrank, Melissa K. Frey, Alicia Latham, Ying L Liu, Carol Aghajanian, Amanda Catchings, Dennis S. Chi, Kenneth Offit, Megha Ranganathan, Nadeem R. Abu-Rustum
Publikováno v:
JCO Oncology Practice. 18:201-209
Pathogenic germline variants underlie up to 20% of ovarian cancer (OC) and are associated with varying degrees of risk for OC. For mutations in high-penetrance genes such as BRCA1/ 2, the role of risk-reducing bilateral salpingo-oophorectomy (RRSO) i
Autor:
Rajmohan Murali, Amir Momeni-Boroujeni, Seth M. Cohen, Kay J. Park, Lora H. Ellenson, Matija Snuderl, Edaise M da Silva, Cheng-Han Lee, Ryma Benayed, Nadeem R. Abu-Rustum, Jason A. Konner, Varshini Vasudevaraja, Marc Ladanyi, Sarah Chiang, Achim A. Jungbluth, Jonathan Serrano, Mark A. Dickson, Britta Weigelt, Carol Aghajanian, Robert A. Soslow, Martee L. Hensley, Arnaud Da Cruz Paula, Esther Oliva, Colin J.R. Stewart
Publikováno v:
Mod Pathol
Uterine perivascular epithelioid cell tumor (PEComa) is a rare mesenchymal neoplasm that occasionally shares morphologic and immunohistochemical overlap with low- and high-grade endometrial stromal sarcoma (LGESS and HGESS). In this study, we sought
Autor:
Gabe S. Sonke, Cara Mathews, Carol Aghajanian, Nicoletta Colombo, Alexandra Leary, Ana Oaknin, Joyce F. Liu, Giovanni Scambia, William H. Bradley, Elizabeth S. Lowe, Jae Weon Kim, Alla Lisyanskaya, Antonio González-Martín, Anne Floquet, Michael Friedlander, Kathleen N. Moore, Ralph Bloomfield, Amit M. Oza, Charlie Gourley, Susana Banerjee, Paul DiSilvestro
Publikováno v:
Colombo, N, Moore, K, Scambia, G, Oaknin, A, Friedlander, M, Lisyanskaya, A, Floquet, A, Leary, A, Sonke, G S, Gourley, C, Banerjee, S, Oza, A, González-martín, A, Aghajanian, C, Bradley, W H, Kim, J, Mathews, C, Liu, J, Lowe, E S, Bloomfield, R & Disilvestro, P 2021, ' Tolerability of maintenance olaparib in newly diagnosed patients with advanced ovarian cancer and a BRCA mutation in the randomized phase III SOLO1 trial ', Gynecologic Oncology . https://doi.org/10.1016/j.ygyno.2021.07.016
Scientia
Scientia
Olaparib; Ovarian cancer; Tolerability Olaparib; Cáncer de ovarios; Tolerabilidad Olaparib; Càncer d'ovaris; Tolerabilitat Objectives In the phase III SOLO1 trial (NCT01844986), maintenance olaparib provided a substantial progression-free survival
Autor:
Aikou Okamoto, Carol Aghajanian, Karina Dahl Steffensen, Gini F. Fleming, Robert L. Coleman, Michael A. Bookman, Elizabeth M. Swisher, Michael Friedlander, Camille Gunderson Jackson, Christine K. Ratajczak, Danielle Sullivan
Publikováno v:
Aghajanian, C, Bookman, M A, Fleming, G F, Swisher, E M, Steffensen, K D, Friedlander, M, Okamoto, A, Jackson, C G, Sullivan, D, Ratajczak, C K & Coleman, R L 2021, ' Progression-free survival by investigator versus blinded independent central review in newly diagnosed patients with high-grade serous ovarian cancer : Analysis of the VELIA/GOG-3005 trial ', Gynecologic Oncology, vol. 162, no. 2, pp. 375-381 . https://doi.org/10.1016/j.ygyno.2021.05.031
OBJECTIVE: In the phase 3 VELIA/GOG-3005 trial, veliparib added to carboplatin-paclitaxel and continued as maintenance improved progression-free survival (PFS) compared to carboplatin-paclitaxel alone in patients with newly diagnosed ovarian carcinom
Autor:
Linda R. Duska, Roisin E. O'Cearbhaill, Sarah W. Gordon, Alice P. Chen, Joan L. Walker, Carol Aghajanian, Saketh R. Guntupalli, Paula M. Fracasso, Cara Mathews, Katherine M. Bell-McGuinn, J. Gillen, Deborah K. Armstrong, Russell J. Schilder, Austin Miller, John L. Hays, Kathleen N. Moore, Heidi J. Gray, Andrea R. Hagemann
Publikováno v:
Gynecol Oncol
Objective To evaluate how women with epithelial ovarian cancer (EOC), dichotomized by BRCA status, tolerate intravenous (IV) or intraperitoneal (IP) chemotherapy given with veliparib and bevacizumab (bev) on a GOG phase I study (GOG 9923, NCT00989651
Autor:
Cara Mathews, Xun Clare Zhou, Peter G. Rose, Virginia L. Filiaci, Michael T. McHale, Amanda Jackson, Heather A. Lankes, Debra L. Richardson, Douglas A. Levine, Carol Aghajanian, Angeles Alvarez Secord, Krishnansu S. Tewari, Kimberly K. Leslie, Casey Cosgrove, Katherine M. Moxley, Summer B. Dewdney, Yovanni Casablanca, David G. Mutch, Eric J. Devor, Megan E McDonald, Kristina W. Thiel, Adrianne R. Mallen
Publikováno v:
Gynecol Oncol
Background Successfully combining targeted agents with chemotherapy is an important future goal for cancer therapy. However, an improvement in patient outcomes requires an enhanced understanding of the tumor biomarkers that predict for drug sensitivi
Autor:
Lora H. Ellenson, Carol Aghajanian, Robert A. Soslow, Marc Ladanyi, Eric Rios-Doria, Nadeem R. Abu-Rustum, Kaled M. Alektiar, Chad M. Vanderbilt, Sarah Chiang, Britta Weigelt, Rajmohan Murali, Amir Momeni-Boroujeni, Wissam Dahoud
Publikováno v:
Clinical Cancer Research. 27:2613-2623
Purpose: Copy number–high endometrial carcinomas were described by The Cancer Genome Atlas as high-grade endometrioid and serous cancers showing frequent copy-number alterations (CNA), low mutational burden (i.e., non-hypermutant), near-universal T
Autor:
Paul Sabbatini, Nadeem R. Abu-Rustum, Renee A. Cowan, Kara Long Roche, Peter B. Bach, Jessica A. Lavery, Elizabeth L. Jewell, Kimberly Dessources, Derman Basaran, Ginger J. Gardner, Roisin E. O'Cearbhaill, Angela K Green, Emeline M. Aviki, Mario M. Leitao, Carol Aghajanian
Publikováno v:
Gynecol Oncol
PURPOSE: We sought to evaluate whether provider volume or other factors are associated with chemotherapy guideline compliance in elderly patients with epithelial ovarian cancer (EOC). METHODS: We queried the SEER-Medicare database for patients ≥66
Autor:
Carol Aghajanian, Paul DiSilvestro, Robert L. Coleman, Bradley J. Monk, Matthew A. Powell, Michael W. Sill, Stephen C. Rubin, Robert S. Mannel, John H. Farley, Leslie M. Randall, Krishnansu S. Tewari
Publikováno v:
Gynecol Oncol
Objective To explore the relationship between tumor size and response to combined anti-vascular targeted therapy using the anti-angiogenesis inhibitor, bevacizumab, and the tubulin-binding vascular disrupting agent, fosbretabulin. Methods An explorat
Autor:
Roisin E. O'Cearbhaill, Qin Zhou, Karen Cadoo, Alexia Iasonos, Jason A. Konner, Paul Sabbatini, Dmitriy Zamarin, Carol Aghajanian, Margaret K. Callahan, Claire F. Friedman, Julia L. Boland
Publikováno v:
Gynecol Oncol
Objective This study aimed to evaluate the utility of serum cancer antigen-125 (CA-125) levels to monitor patients with epithelial ovarian cancer (EOC) undergoing immune checkpoint inhibitor (ICI) therapy. Method This was a single-center retrospectiv